About RedHill

RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

The Company’s current product pipeline includes:

TALICIA - An oral combination therapy for Helicobacter pylori infection, with positive results from a first Phase III study and an ongoing confirmatory Phase III study.

RHB-104 - An oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status and a planed pivotal Phase III study for nontuberculous mycobacteria (NTM) infections.

BEKINDA® (RHB-102) - A once-daily oral pill formulation of ondansetron with successful top-line results from a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D.

RHB-106 - An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.

YELIVA® (ABC294640) - A Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications

MESUPRON - A Phase II-stage, orally-administered, first-in-class protease inhibitor with a planned Phase I/II study for unresectable pancreatic cancer. 

RIZAPORT® (RHB-103) - An oral thin film formulation of rizatriptan, for the treatment of acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015.

RedHill promotes two gastrointestinal products in the U.S. - Donnatal®, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis, and EnteraGam®, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.